**Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy**

**Purpose**

Phase II Study of efficacy and safety of buparlisib (BKM120) plus paclitaxel versus placebo plus paclitaxel in recurrent or metastatic Head and Neck cancer previously pre-treated with a platinum therapy.

<table>
<thead>
<tr>
<th>Condition</th>
<th>Intervention</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Platinum Pre-treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma</td>
<td>Drug: Paclitaxel Drug: Buparlisib Drug: Buparlisib Placebo</td>
<td>Phase 2</td>
</tr>
</tbody>
</table>

**Study Type:** Interventional  
**Study Design:** Allocation: Randomized  
Endpoint Classification: Safety/Efficacy Study  
Intervention Model: Parallel Assignment  
Masking: Double Blind (Subject, Investigator)  
Primary Purpose: Treatment

**Official Title:** Double Blind, Placebo Controlled Study Assessing the Efficacy of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Patients With Platinum Pre-treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

**Resource links provided by NLM:**

- [Drug Information available for: Paclitaxel](http://www.nlm.nih.gov/medlineplus/druginfo/meds/a690732.html)
- [Genetic and Rare Diseases Information Center resources: Squamous Cell Carcinoma of the Head and Neck](http://rarediseases.info.nih.gov/dissease/SquamousCellCarcinomaOfTheHeadAndNeck)
- [U.S. FDA Resources](http://www.fda.gov)

**Further study details as provided by Novartis:**

**Primary Outcome Measures:**

- Progression Free Survival (PFS) [ Time Frame: at 4 weeks after study treatment start ] [ Designated as safety issue: No ]  
  To estimate the efficacy of buparlisib in combination with paclitaxel

**Secondary Outcome Measures:**

- Overall Survival [ Time Frame: every 3 months for 2 years ] [ Designated as safety issue: No ]  
  To assess the efficacy of the combination with paclitaxel in this patient population in terms of overall survival

- Safety and Tolerability - frequency and severity of adverse events [ Time Frame: on an ongoing basis for a maximum of 2 years. ] [ Designated as safety issue: Yes ]
To assess the safety and tolerability of buparlisib in combination with paclitaxel in this patient population

- Overall Response Rate (ORR) [Time Frame: at 4 weeks after study treatment start and every 6 weeks afterwards until 2 years.][Designated as safety issue: No]
- Time to Response (TTR) [Time Frame: at 4 weeks after study treatment start and every 6 weeks afterwards until 2 years.][Designated as safety issue: No]
- Disease Control Rate (DCR) [Time Frame: at 4 weeks after study treatment start and every 6 weeks afterwards until 2 years.][Designated as safety issue: No]
- Duration of Response (DoR) [Time Frame: at 4 weeks after study treatment start and every 6 weeks afterwards until 2 years.][Designated as safety issue: No]
- Change from baseline in the global health status/QOL and pain scale scores of the EORTC QLQ-C30 and QLQ-HN35 [Time Frame: baseline and every 6 weeks after randomization for 2 years.][Designated as safety issue: No]

To characterize the pharmacokinetics of buparlisib given in combination with paclitaxel

PK Sampling [Time Frame: Cycle 1, Day 1 of each cycle until Cycle 6][Designated as safety issue: No]

Estimated Enrollment: 150
Study Start Date: October 2013
Estimated Study Completion Date: July 2015
Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)

<table>
<thead>
<tr>
<th>Arms</th>
<th>Assigned Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Experimental: Buparlisib + Paclitaxel buparlisib (BKM120) 100 mg daily + Paclitaxel</td>
<td>Drug: Paclitaxel Other Name: This is a combination trial, all patients will be treated with paclitaxel +/- buparlisib. Drug: Buparlisib Other Name: BKM120</td>
</tr>
<tr>
<td>Placebo Comparator: Buparlisib matching placebo + Paclitaxel buparlisib matching placebo</td>
<td>Drug: Paclitaxel Other Name: This is a combination trial, all patients will be treated with paclitaxel +/- buparlisib. Drug: Buparlisib Placebo</td>
</tr>
</tbody>
</table>

Detailed Description:
The primary endpoint is PFS and the key secondary endpoint is Overall Survival.

Eligibility

Ages Eligible for Study: 18 Years and older
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:
- Patient has histologically/cytologically-confirmed HNSCC.
- Patient has archival or fresh tumor tissue for the analysis of PI3K-related biomarkers. One tumor block (preferred) or a minimum of 12 unstained slides to be provided. Enrollment in the study is contingent on confirmation of an adequate amount of tumor tissue.
- Patients with recurrent or metastatic disease resistant to platinum-based chemotherapy (defined as progression while on platinum-based chemotherapy given in the recurrent/metastatic setting). Pretreatment with cetuximab is allowed.
- Measurable disease as determined by per RECIST criteria v1.1. If the only site of measurable disease is a previously irradiated lesion, documented progression of disease and a 4 week period since radiotherapy completion is required.
- Adequate bone marrow function and organ function
- ECOG Performance Status ≤ 1

Exclusion Criteria:
- Patient has received previous treatment with any AKT, mTOR inhibitors or PI3K pathway inhibitors;
- Patient treated with more than one prior chemotherapy regimen for recurrent/metastatic disease
- Patient has symptomatic CNS metastases. Patients with asymptomatic CNS metastases may participate in this trial. The patient must have completed any prior local treatment for CNS metastases ≥ 29 days prior to the start of study treatment (including radiotherapy and/or surgery).
and must have stable low dose of corticosteroid therapy;

- Patient has not recovered to ≤ grade 1 (except alopecia) from related side effects of any prior antineoplastic therapy
- Patient has any of the following cardiac abnormalities: symptomatic congestive heart failure, history of documented congestive heart failure (New York Heart Association functional classification III-IV), documented cardiomyopathy, Left Ventricular Ejection Fraction (LVEF) ≤50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO); myocardial infarction ≤ 6 months prior to enrolment, unstable angina pectoris, serious uncontrolled cardiac arrhythmia, symptomatic pericarditis, QTcF > 480 msec on the screening ECG (using the QTcF formula);

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01852292

Contacts

Contact: Novartis Pharmaceuticals 1-888-669-6682
Contact: Novartis Pharmaceuticals

Sponsors and Collaborators

Novartis Pharmaceuticals

Investigators

Study Director: Novartis Pharmaceuticals  Novartis Pharmaceuticals

More Information

No publications provided

Responsible Party: Novartis (Novartis Pharmaceuticals)
ClinicalTrials.gov Identifier: NCT01852292  History of Changes
Other Study ID Numbers: CBKM120H2201
Study First Received: May 8, 2013
Last Updated: January 9, 2014
Health Authority: United States: Food and Drug Administration
Canada: Health Canada
Australia: Department of Health and Ageing Therapeutic Goods Administration
France: ANSM
Germany: BfArM
Hungary: National Institute of Pharmacy
Italy: AIFA
Japan: Pharmaceuticals and Medical Devices Agency
Poland: Ministry of Health
Russia: Ministry of Health of the Russian Federation
South Korea: Food and Drug Administration
Spain: Agency of Medicines & Health Products
Switzerland: Swissmedic
Taiwan: Center for Drug Evaluation
Thailand: Food and Drug Administration
United Kingdom: Medicines and Healthcare Products Regulatory Agency
India: Indian Council of Medical Research
Ireland: Health & Safety Authority

Keywords provided by Novartis:
- Head and neck squamous cell carcinoma,
- recurrent,
- metastatic,
- BKM120

Additional relevant MeSH terms:
- Carcinoma
- Carcinoma, Squamous Cell
- Head and Neck Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Squamous Cell
- Neoplasms by Site
- Paclitaxel
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Molecular Mechanisms of Pharmacological Action
- Pharmacologic Actions
- Antineoplastic Agents, Phytochemical
- Antineoplastic Agents
- Therapeutic Uses

http://clinicaltrials.gov/ct2/show/NCT01852292?term=CBKM120H2...